Clinical Trials
19 trialsNCT04638725 2026-06-04
SIGHER
Centre Paul Strauss
Recruiting
NCT07616440 2026-06-04
Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Recruiting
NCT03125928 2026-05-22
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT03738553 2026-05-04
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
Terminated
NCT05705401 2026-04-27
HERO
NRG Oncology
Phase 3 Active not recruiting
NCT06518382 2026-04-15
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
IRCCS Ospedale San Raffaele
Recruiting
NCT07470203 2026-03-13
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT04273555 2026-02-06
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT07281001 2025-12-15
Traderrus
Blokhin's Russian Cancer Research Center
Phase NA Recruiting
NCT03571633 2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2 Active not recruiting
NCT05982678 2025-11-26
ANISE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04419181 2025-10-14
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Phase 2 Withdrawn
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT07166367 2025-09-10
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
National Cancer Centre, Singapore
Phase 2 Terminated
NCT07115095 2025-08-11
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
Phase NA Completed
NCT06123988 2025-08-06
FastER
University of Miami
Phase NA Recruiting
NCT06973525 2025-08-05
HER2-DM-NACT
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06992882 2025-07-18
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Fudan University
Phase 3 Recruiting
NCT07019272 2025-06-13
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Hebei Medical University Fourth Hospital
Not yet recruiting